Iqvia 559K share Block Trade priced at $263.00 » 08:2811/3011/30/21
The deal range was…
The deal range was $263.00-$264.00. Morgan Stanley acted as sole book running manager for the offering.
Iqvia 559K share Block Trade; price range $263.00-$264.00 » 16:4911/2911/29/21
Morgan Stanley is acting…
Morgan Stanley is acting as sole book running manager for the offering.
|Over a week ago|
Iqvia added to US 1 list at BofA » 09:2611/1811/18/21
BofA says its US 1 list…
BofA says its US 1 list is intended to represent a collection of the best investment ideas drawn from the firm's Buy-rated, US-listed stocks covered by BofA Global Research fundamental equity research analysts.
Iqvia price target raised to $290 from $282 at Mizuho » 06:3811/1811/18/21
Mizuho analyst Ann Hynes…
Mizuho analyst Ann Hynes raised the firm's price target on Iqvia to $290 from $282 and keeps a Buy rating on the shares post the investor day. Iqvia raised its intermediate growth target for revenue and adjusted EBITDA by 250 basis points at the midpoint, and maintained double-digit adjusted earnings growth, Hynes tells investors in a research note. The analyst believes the company's earnings visibility remains high in the near- to mid-term.
Iqvia price target raised to $261 from $250 at Piper Sandler » 04:5611/1811/18/21
Piper Sandler analyst…
Piper Sandler analyst Sean Wieland raised the firm's price target on Iqvia to $261 from $250 and keeps a Neutral rating on the shares following the investor day. The company laid out a vision for $20B in revenue by fiscal 2025, Wieland tells investors in a research note. The analyst says that while sales momentum has been strong and ahead of targets, he's concerned about Covid revenue tailwinds subsiding as well as rising wages and retention costs.
Iqvia price target raised to $290 from $270 at KeyBanc » 07:4911/1711/17/21
KeyBanc analyst Donald…
KeyBanc analyst Donald Hooker raised the firm's price target on Iqvia to $290 from $270 and keeps an Overweight rating on the shares after management hosted an Investor Day at which it provided a better-than-expected top- and bottom-line growth outlook for the next 3-plus years. The analyst now sees Iqvia generating low-teens EBITDA growth in 2022 and 2023, despite the loss of $1B-plus of revenue in 2022 due to the completion of large COVID-19 clinical trials. The wind-down of these large COVID-19 clinical trials had been a concern for 2022, Hooker notes
Iqvia price target raised to $320 from $300 at Citi » 07:2511/1711/17/21
Citi analyst Patrick…
Citi analyst Patrick Donnelly raised the firm's price target on Iqvia to $320 from $300 and keeps a Buy rating on the shares. During its investor day, the company discussed its initial 2022 guidance and 2022-2025 medium term outlook, highlighting the "robust" biopharma backdrop and its favorable position for hybrid clinical trials as key growth drivers, Donnelly tells investors in a research note.
Iqvia price target raised to $310 from $298 at UBS » 06:5811/1711/17/21
UBS analyst Dan Brennan…
UBS analyst Dan Brennan raised the firm's price target on Iqvia to $310 from $298 and keeps a Buy rating on the shares. The company's investor day presentation was "upbeat" with initial FY22 guidance and updated long-term targets coming ahead of estimates, the analyst tells investors in a research note. Brennan adds that he continues to see an attractive opportunity given accelerating growth, share gains, and the positive industry backdrop.
Iqvia to hold a meeting » 09:2911/1611/16/21
Financial Analyst and…
Financial Analyst and Investor Meeting to be held on November 16 at 10 am. Webcast Link
Evercore ISI raises Iqvia price target to $320, adds to tactical outperform list » 08:4411/1211/12/21
Evercore ISI analyst…
Evercore ISI analyst Elizabeth Anderson raised the firm's price target on Iqvia to $320 from $300 and keeps an Outperform rating on the shares while adding the stock to Evercore ISI's TAP Outperform list ahead of the company's investor day next Tuesday, November 16. She sees upside to Street estimates for 2022 and also views the investor day as an opportunity for management to provide a deeper dive that should give investors greater certainty into the TAS segment's outlook, Anderson said.